Assistant Professor, Obstetrics and Gynecology, Yale University School of Medicine
Obstetrics & Gynecology
Dr. Elena S. Ratner, MD
|
|
Give Review
Elena Ratner practices Obstetrics & Gynecology. He studied medicine at University at Buffalo, School of Medicine and Biomedical Sciences. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Doctor Elena S. Ratner, MD has written publications. He has 35 publications published with PubMed. The lastest publication is: 'Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
- Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
- Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.
- A Series of Malignant Ovarian Cancers Arising From Within a Mature Cystic Teratoma: A Single Institution Experience.
- Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube Cancers: A re...
- Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterin...
- Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.
- Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial Cancer in vitro and in vivo.
- Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian Cancer cell lines in vi...
- T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous Carcinoma in vitro and in vivo.
- Triapine Disrupts CtIP-Mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors.
- Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian Cancer patients treated with neoadj...
- Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian Cancer: implications for ovarian Cancer im...
- Tubulin-?-III overexpression by uterine serous Carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
- Landscape of somatic single-nucleotide and copy-number mutations in uterine serous Carcinoma.
- Syndrome of Inappropriate Antidiuretic Hormone after vinorelbine treatment.
- Oophorectomy: the debate between Ovarian conservation and elective oophorectomy.
- Sexual function in older women after oophorectomy.
- Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian Cancer.
- A survey of gynecologic oncologists regarding the End-of-Life discussion: A pilot study.
- MicroRNA signatures differentiate uterine Cancer tumor subtypes.
- The KRAS-Variant Genetic Test As a Marker of Increased Risk of Ovarian Cancer.
- Brain metastases in epithelial ovarian and primary peritoneal Carcinoma.
- The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905.
- Cervical Carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 ...
- Proteomic but not enzyme-linked immunosorbent assay technology detects amniotic fluid monomeric calgranulins from their complexed calprotectin form.
- Uterine and Ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody.
- Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial Cancer.
- The significance of perineural invasion in early-stage Cervical cancer.
- A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung Cancer risk.
- MicroRNA signatures differentiate melanoma subtypes.
- A KRAS-variant in ovarian Cancer acts as a genetic marker of Cancer risk.
- Sexuality and intimacy after gynecological Cancer.
- Sexual satisfaction in the elderly female population: A special focus on women with gynecologic pathology.
Procedures Preformed
- Colporrhaphy
- Colposcopy
- Destruction or Excision of Lesion of Cervix (incl. LEEP)
- Destruction or Excision of Vaginal Lesions
- View All
Conditions Treated
- Carcinoma in Situ
- Cervical Cancer
- Fallopian Tube Cancer
- Ovarian Cancer
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Pathway X Ind PPO Direct Access CT
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Connecticare HMO
- Connecticare POS
- CoreSource
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Yale-New Haven Hospital -
University at Buffalo, School of Medicine and Biomedical Sciences
Drug Facts
| NPI NUMBER | 1588846463 | |
| NPPES Provider LastName | RATNER | |
| NPPES Provider FirstName | ELENA | |
| NPPES Provider ZIPCode | 065191369 | |
| NPPES Provider State | CT | |
| Specialty Description | Gynecological/Oncology | |
| Total Claim Count | 67.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1588846463 |
| Last Name Of The Provider | RATNER |
| First Name Of The Provider | ELENA |
| View All |
Similar Doctors
|
|
Dr. Stephanie R. Vaz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas J. Rutherford, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Peter E. Schwartz, MD |
|
|
Dr. Stephanie S. Spangler, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joshua A. Copel, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Nancy L. Stanwood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Paidas, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Maria C. De Leon, MD |
|
|
Dr. Katherine S. Kohari, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alessandro Santin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Cackovic, MD
This Doctor is OpenDoctor Recommended.
|